2026 Interim report
Filed with HKEX · Stock code 1177 ·
6ix hasn’t read this filing yet.
Sino Biopharmaceutical Limited on 6ix
Earlier from Sino Biopharmaceutical
- Voluntary announcement - acceptance of new drug application for TQH2722 injection
- Voluntary announcement - acceptance of new drug application for TQB2102 injection "HER2 bispecific adc"
- Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
- AI and Content Reshape Attractions & Tours at Trip.com Group's Global Partner Forum
- Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11
Later from Sino Biopharmaceutical
- Notification letter and reply form for registered shareholders
- Notification letter and request form for non-registered shareholders
- Voluntary announcement - enter into strategic biosimilars partnership with stada
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - completion of all subjects enrollment in the phase iii registrational clinical trial of TQC3721 inhalation suspension "PDE3/4 inhibitor"
Follow Sino Biopharmaceutical into a list and get an email when it puts out news.
Follow Sino Biopharmaceutical